Opinion
Video
Switching Between BTK Inhibitors in CLL
Author(s):
Panelists discuss how decisions to switch between Bruton tyrosine kinase (BTK) inhibitors are driven by multiple factors including intolerable toxicities, development of resistance mutations, disease progression, drug interactions, and patient preferences, with pirtobrutinib emerging as a particularly valuable option for patients with BTK C481 mutations or those who have exhausted other BTK inhibitor (BTKi) options.
Video Player is loading.
Video content above is prompted by the following:
- What factors typically drive decisions to switch between BTK inhibitors: managing toxicity, addressing disease progression, or other considerations?
- How do these factors influence your decision on which therapy to switch to, either within the BTKi class or outside of it? Where does pirtobrutinib fit into this decision?
Related Videos
Patient-Centered Selection of BTK Inhibitors: Balancing Clinical Factors and Patient Preferences
The Value Proposition: Justifying the Investment in HS Centers of Excellence
Impact of BTK Inhibitors on Treatment Paradigm of CLL and MCL
Diving into the COVID-19 Pandemic’s Impact on Ovarian Cancer, Remission Rates
Closing Thoughts on Iron Deficiency Anemia
The Future of IV Iron Administration
Final Takeaways From the Panelists
Future Treatment of Patients With Alopecia Areata
Allogeneic vs Autologous CAR T-Cell Therapy Explained
Assessing Patient Confidence With Biosimilars
Related Content
Published: February 25th 2025 | Updated: February 25th 2025
Dry Eye Symptom Frequency, Severity Reduced When Using Perfluorohexyloctane
